Showing results (271-280 of 358) with videos related to

Sort By:
Pageof 36
Breast Cancer Research : BCR|July 19, 2022
Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancerAnn Hanna, Mellissa J Nixon, M Valeria Estrada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2016
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast CancerIngrid A Mayer, Vandana G Abramson, Luigi Formisano, et al.
Cancer Research|September 13, 2011
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancerEmily M Fox, Todd W Miller, Justin M Balko, et al.
Cancer Research|January 9, 2016
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung CancerKatherine R Amato, Shan Wang, Li Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancerIngrid A Mayer, Vandana G Abramson, Steven J Isakoff, et al.
The Journal of Clinical Investigation|February 5, 2020
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapyBalamayoora Theivanthiran, Kathy S Evans, Nicholas C DeVito, et al.
Ceskoslovenska Patologie|October 12, 2022
A rational approach to the CNS tumors diagnosticsLenka Krsková, Barbora Šípalová, Tereza Němečková, et al.
Journal for Immunotherapy of Cancer|February 5, 2024
Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistanceJamaal L James, Brandie C Taylor, Margaret L Axelrod, et al.
Cancer Research Communications|October 28, 2022
Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast CancerMargaret L Axelrod, Yu Wang, Yaomin Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2025
Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast CancerPaula I Gonzalez-Ericsson, Nisha Unni, Komal Jhaveri, et al.
Pageof 36